Pentagon makes costly foray into biodefense drug business
David WillmanWASHINGTON — Despite intense pressure to hold down federal spending, the Defense Department is launching a high-priced effort to create its own production pipeline for vaccines and biodefense drugs — an initiative that defies the advice of government-hired experts and duplicates what another agency is doing.
Construction began in late October on a plant in north Florida that will produce flu vaccine and specialized medicines for the Pentagon to protect military personnel against germ warfare agents.
Pour citer cette ressource :
"Pentagon makes costly foray into biodefense drug business", La Clé des Langues [en ligne], Lyon, ENS de LYON/DGESCO (ISSN 2107-7029), novembre 2013. Consulté le 01/12/2023. URL: https://cle.ens-lyon.fr/anglais/archives/archives-revue-de-presse/pentagon-makes-costly-foray-into-biodefense-drug-business